Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes
In brief
Ocrelizumab lowered progression risk nearly fourfold in high B-cell, NfL group
Among people with relapsing multiple sclerosis who had high baseline B-cell levels and high neurofilament light, disability progression risk was nearly four times lower with ocrelizumab than with interferon beta-1a. Across phase 3 trial data, detectable B cells during treatment also tracked with more new or enlarging brain lesions; whether these markers should guide treatment choices needs further validation.
- Journal
- Neurology(R) neuroimmunology & neuroinflammation (Q1)
- Published
- 12 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Stephen L Hauser, Nicolas Strauli, Koji Shinoda, Anastasiia Raievska, Christopher Harp, Harold Koendgen, et al.
- PMID
- 43019492
- DOI
- 10.1212/NXI.0000000000200665
Why clinicians should know about it
- Picked for Immunology and Allergy (top studies of the week, 15 November 2026): B-cell depletion and biomarkers linked to clinical MS outcomes
- Picked for Neurology (clinical) (top studies of the week, 15 November 2026): Phase III trial data link B-cell biomarkers with MS outcomes
Abstract
BACKGROUND AND OBJECTIVES: Anti-CD20 B-cell-depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS). METHODS: Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses. RESULTS: Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8-4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: -1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a-treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions (p < 0.01). When interferon beta-1a-treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001). DISCUSSION: Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.